Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levocetirizine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 4/20 | 1.00 |
| ▸ | DRD3 | P35462 | 4/20 | 0.98 |
| ▸ | USP2 | O75604 | 3/20 | 0.98 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.98 |
| ▸ | HRH2 | P25021 | 2/20 | 0.98 |
| ▸ | HTR2A | P28223 | 2/20 | 0.98 |
| ▸ | HTR2B | P41595 | 2/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.98 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.98 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.98 |
| ▸ | TEK | Q02763 | 1/20 | 0.98 |
| ▸ | DRD2 | P14416 | 3/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.73 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.73 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.73 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.73 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.73 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.73 |
| ▸ | DRD4 | P21917 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levocetirizine SCHEMBL144375 | 1.00 | HRH1 (1.00) | HRH1DRD3USP2TDP1HRH2 | |
| Cetirizine SCHEMBL41108 | 1.00 | HRH1 (1.00) | HRH1DRD3USP2TDP1HRH2 | |
| Cetirizine SCHEMBL17800801 | 1.00 | HRH1 (1.00) | HRH1DRD3USP2TDP1HRH2 | |
| Cetirizine SCHEMBL41107 | 1.00 | HRH1 (1.00) | HRH1DRD3USP2TDP1HRH2 | |
| Cetirizine SCHEMBL5520719 | 1.00 | HRH1 (1.00) | HRH1DRD3USP2TDP1HRH2 | |
| Levocetirizine SCHEMBL4914 | 0.99 | DRD3 (1.00) | HRH1DRD3USP2TDP1HRH2 | |
| Levocetirizine SCHEMBL5935097 | 0.99 | DRD3 (1.00) | HRH1DRD3USP2TDP1HRH2 | |
| Cetirizine SCHEMBL13724610 | 0.99 | DRD3 (1.00) | HRH1DRD3USP2TDP1HRH2 | |
| Cetirizine SCHEMBL4176 | 0.99 | DRD3 (1.00) | HRH1DRD3USP2TDP1HRH2 | |
| Cetirizine SCHEMBL2455487 | 0.99 | DRD3 (1.00) | HRH1DRD3USP2TDP1HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 413 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4654949-A1 | USE OF VITAMIN E TPGS AS A TASTE MASKING AGENT FOR BITTER DRUGS | Hyloris Developments SA (BE) | 2025-12-03 | — | — | EP | claimed |
| CN-120064494-A | Method for detecting p-chlorobenzhydryl piperazine in levocetirizine hydrochloride particles | 康芝药业股份有限公司 | 2025-05-30 | — | — | CN | claimed |
| CN-116492295-B | Levocetirizine hydrochloride oral solution of ligazine | 新乡医学院第三附属医院 | 2025-05-27 | — | — | CN | claimed |
| CN-119868269-A | Stable levocetirizine hydrochloride eye drop composition and preparation method thereof | 北京汇恩兰德制药有限公司 | 2025-04-25 | — | — | CN | claimed |
| CN-119818437-A | Levocetirizine hydrochloride eye drop composition, preparation method and application | 北京汇恩兰德制药有限公司 | 2025-04-15 | — | — | CN | claimed |
| CN-119700684-A | Levocetirizine hydrochloride particles and preparation method thereof | 康芝药业股份有限公司 | 2025-03-28 | — | — | CN | claimed |
| CN-118717839-A | Combined medicine for treating chronic urticaria and application thereof | 四川省医学科学院·四川省人民医院 | 2024-10-01 | — | — | CN | claimed |
| CN-116203156-B | Detection method of cetirizine oral liquid preparation related impurities | 北京柏雅联合药物研究所有限公司 | 2024-09-03 | — | — | CN | claimed |
| WO-2024156799-A1 | USE OF VITAMIN E TPGS AS A TASTE MASKING AGENT FOR BITTER DRUGS | HYLORIS DEVELOPMENTS SA (BE) | 2024-08-02 | — | — | WO | claimed |
| CN-118191142-A | Method for determining and separating levocetirizine hydrochloride and related substances thereof | 南京海京康医药科技有限公司 | 2024-06-14 | — | — | CN | claimed |
| US-20160303156-A1 | PHARMACEUTICAL COMPOSITION COMPRISING NARINGIN AND LEVOCETIRIZINE HYDROCHLORIDE, AND PREPARATIONS THEREOF | SUN YAT-SEN UNIVERSITY (CN) | 2016-10-20 | — | — | US | claimed |
| US-20160279071-A1 | ORALLY DISINTEGRATING POROUS FILM COMPRISING PHARMACOLOGICAL ACTIVE INGREDIENT AND METHOD FOR PREPARING SAME | SEOUL PHARMA. CO., LTD. (KR) | 2016-09-29 | — | — | US | claimed |
| EP-3069716-A1 | ORALLY DISINTEGRATING POROUS FILM COMPRISING PHARMACOLOGICAL ACTIVE INGREDIENT AND METHOD FOR PREPARING SAME | Seoul Pharma. Co., Ltd. (KR) | 2016-09-21 | — | — | EP | claimed |
| EP-3069723-A1 | NARINGIN AND LEVOCETIRIZINE HYDROCHLORIDE PHARMACEUTICAL COMPOSITION AND PREPARATION THEREOF | Sun Yat-Sen University (CN) | 2016-09-21 | — | — | EP | claimed |
| US-20150359566-A1 | THERAPEUTIC SUBSTANCE TRANSFER CATHETER AND METHOD | SILLENDER MARK (US) | 2015-12-17 | — | — | US | claimed |
| EP-2953678-A1 | THERAPEUTIC SUBSTANCE TRANSFER CATHETER AND METHOD | Sillender, Mark (AU) | 2015-12-16 | — | — | EP | claimed |
| WO-2014121332-A1 | THERAPEUTIC SUBSTANCE TRANSFER CATHETER AND METHOD | SILLENDER MARK (AU) | 2014-08-14 | — | — | WO | claimed |
| WO-2013015545-A1 | COMPOSITION FOR EDIBLE FILM AND PHARMACEUTICAL PREPARATION FOR EDIBLE FILM CONTAINING DRUGS | KWANG DONG PHARM. CO., LTD. (KR) | 2013-01-31 | — | — | WO | claimed |
| WO-2005041969-A1 | PHARMACEUTICAL PRODUCT COMPRISING A BETA-2 ADRENERGIC AGONIST AND AN H1-RECEPTOR ANTAGONIST | CIPLA LIMITED (IN) | 2005-05-12 | — | — | WO | claimed |
| WO-2005007145-A1 | PHARMACEUTICAL PRODUCT COMPRISING A BETA-2 ADRENOCEPTOR AGONIST AND AN ANTIHISTAMINE | CIPLA LIMITED (IN) | 2005-01-27 | — | — | WO | claimed |